多黏菌素甲磺酸钠在重症患者中的疗效与安全性:基于蒙特卡洛模拟的体外研究
该研究收集2012年9月至2015年9月安徽省细菌耐药监测网35个ICU的321株PDR-AB和204株PDR-PA,用E-test测定多黏菌素MIC,并对CMS方案(1 MU q8h、2 MU q8h、3 MU q8h)进行蒙特卡洛模拟,计算AUC24/MIC>60的达标概率(PTA)和累积反应分数(CFR),以及平均24小时血药浓度达4 mg/L的肾毒性风险。结果显示所有菌株对多黏菌素敏感,PDR-AB的MIC50/90为0.5/1.0 mg/L,PDR-PA为0.5/1.5 mg/L。推荐剂量1 MU q8h在CLCr<60 mL/min时CFR高(PDR-AB 89.78%,PDR-PA 81.06%)但肾毒性风险>32.51%,且对MIC≥1 mg/L菌株PTA<66.56%;在CLCr≥60-120 mL/min时CFR低(PDR-AB 56.97%-69.31%,PDR-PA 44.76%-56.94%)。2 MU q8h在CLCr≥60-120 mL/min时CFR 77.45%-92.87%、肾毒性风险<0.15%,但对MIC≥1 mg/L菌株PTA<75.36%。3 MU q8h在CLCr≥90-120 mL/min时CFR>89.24%,仅对MIC≥1.5 mg/L菌株PTA<76.20%,但肾毒性风险>33.68%。作者认为应考虑测定MIC、个体化CMS治疗
要点
- 所有321株PDR-AB和204株PDR-PA均对多黏菌素敏感,PDR-AB的MIC50/90为0.5/1.0 mg/L,PDR-PA为0.5/1.5 mg/L。
- CLCr<60 mL/min用1 MU q8h时CFR高(PDR-AB 89.78%,PDR-PA 81.06%)但肾毒性风险>32.51%,且对MIC≥1 mg/L菌株PTA<66.56%。
- CLCr≥60-120 mL/min用1 MU q8h时CFR低(PDR-AB 56.97%-69.31%,PDR-PA 44.76%-56.94%)。
- CLCr≥60-120 mL/min用2 MU q8h时CFR 77.45%-92.87%、肾毒性风险<0.15%,但对MIC≥1 mg/L菌株PTA<75.36%。
- 3 MU q8h在CLCr≥90-120 mL/min时CFR>89.24%,仅对MIC≥1.5 mg/L菌株PTA<76.20%,但肾毒性风险>33.68%。
适用人群与场景
- 35个二级及以上医院ICU收治的重症患者分离的321株PDR-AB和204株PDR-PA。
- 模拟的肾功能分层为CLCr<60、≥60-90、≥90-120 mL/min。
诊断标准与关键阈值
- 多黏菌素药敏以E-test测定MIC,所有菌株均敏感。
- 目标暴露:24小时AUC/MIC比值>60。
- CFR≥90%为最佳给药方案,>80%为次优给药方案。
- 肾毒性风险以平均24小时血药浓度达4 mg/L的概率预测。
处置流程与药物剂量
- 1 MU q8h(推荐剂量):CLCr<60 mL/min时CFR高(PDR-AB 89.78%,PDR-PA 81.06%)但肾毒性风险>32.51%,对MIC≥1 mg/L菌株PTA<66.56%;CLCr≥60-120 mL/min时CFR低(PDR-AB 56.97%-69.31%,PDR-PA 44.76%-56.94%)。
- 2 MU q8h:CLCr≥60-120 mL/min时CFR 77.45%-92.87%、肾毒性风险<0.15%,但对MIC≥1 mg/L菌株PTA<75.36%。
- 3 MU q8h:CLCr≥90-120 mL/min时CFR>89.24%,仅对MIC≥1.5 mg/L菌株PTA<76.20%,但肾毒性风险>33.68%。
研究设计与关键结果
- 研究类型:基于蒙特卡洛模拟的体外研究;样本量:321株PDR-AB和204株PDR-PA;来源:安徽省细菌耐药监测网35个ICU,2012年9月至2015年9月。
- 所有菌株对多黏菌素敏感,PDR-AB的MIC50/90为0.5/1.0 mg/L,PDR-PA为0.5/1.5 mg/L。
- 1 MU q8h在CLCr<60 mL/min时CFR:PDR-AB 89.78%,PDR-PA 81.06%;肾毒性风险>32.51%;对MIC≥1 mg/L菌株PTA<66.56%。
- 1 MU q8h在CLCr≥60-120 mL/min时CFR:PDR-AB 56.97%-69.31%,PDR-PA 44.76%-56.94%。
- 2 MU q8h在CLCr≥60-120 mL/min时CFR 77.45%-92.87%,肾毒性风险<0.15%,对MIC≥1 mg/L菌株PTA<75.36%。
- 3 MU q8h在CLCr≥90-120 mL/min时CFR>89.24%,仅对MIC≥1.5 mg/L菌株PTA<76.20%,肾毒性风险>33.68%。
证据类型、等级与局限
- 证据类型:体外研究(蒙特卡洛模拟)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为应考虑测定MIC、个体化CMS治疗和治疗药物浓度监测,以达到最佳药物暴露并确保CMS安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy and safety of colistimethate sodium (CMS) for the treatment of critical patients infected by pan-drug resistant Acinetobacter baumannii (PDR-AB) or pan-drug resistant Pseudomonas aeruginosa (PDR-PA).
METHODS: 321 isolates of PDR-AB and 204 isolates of PDR-PA from critical patients admitted to 35 intensive care units (ICUs) of grade two or above were collected from the Anhui Antimicrobial Resistance Investigation Net (AHARIN) program from September 2012 to September 2015, while the minimal inhibitory concentrations (MIC) of colistin were determined by the E-test. A series of Monte Carlo simulations was performed for CMS regimens (1 MU q8h, 2 MU q8h, and 3 MU q8h, and MU meant a million of unit), and the probability of achieving a 24-hour area under the drug concentration time curve (AUC24)/MIC ratio > 60 and risk of nephrotoxicity for each dosing regimen was calculated. Each simulation was run over three CLCr ranges: < 60, ≥ 60-90, ≥ 90-120 mL/min. The probability of target attainment (PTA) for the AUC24/MIC ratio was calculated using the partial MIC value, while the cumulative fraction of response (CFR) was determined by integrating each PTA with the MIC distributions, the value greater than or equal to 90% or more than 80% was set as the optimal dosing regimen or suboptimal dosing regimen respectively. The probability of average 24-hour serum concentrations up to 4 mg/L for three dosage regimens was used to predict the risks of nephrotoxicity.
RESULTS: All 321 isolates of PDR-AB and 204 isolates of PDR-PA were susceptible to colistin, the MIC50/90 against PDR-AB were 0.5 mg/L and 1.0 mg/L, and those against PDR-PA were 0.5 mg/L and 1.5 mg/L, respectively. When recommended dose (1 MU q8h) was used for patients with CLCr of < 60 mL/min, high CFR value (89.78% for PDR-AB, 81.06% for PDR-PA) were obtained, but with a high risks of nephrotoxicity (> 32.51%). Moreover, low value of PTA (< 66.56%) was yielded for isolates with MIC of ≥ 1 mg/L. Recommended dose also yielded a low CFR value (56.97%-69.31% for PDR-AB, 44.76%-56.94% for PDR-PA) in patients with CLCr of ≥ 60-120 mL/min. When dose was increased to 2 MU q8h, CFR (77.45%-92.87%) and the risks of nephrotoxicity (< 0.15%) was optimal for patients with CLCr ≥ 60-120 mL/min, but low value of PTA (< 75.36%) was also yielded for isolates with MIC of ≥ 1 mg/L. The most aggressive dose of 3 MU q8h provided high CFR (> 89.24%) even in patients with CLCr ≥ 90-120 mL/min, and PTA was < 76.20% only for isolates with MIC of ≥ 1.5 mg/L, but this dosing scheme was associated with unacceptable risks of nephrotoxicity (> 33.68%).
CONCLUSIONS: Measurement of MIC, individualized CMS therapy and therapeutic drug-level monitoring should be considered to achieve the optimal drug exposure and ensure the safety of CMS.
参考来源
- Pan A, Mei Q, Yang T, et al. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28524024. doi:10.3760/cma.j.issn.2095-4352.2017.05.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。